A retrospective study to determine impact of different clinical factors on outcomes of pembrolizumab versus pembro-chemotherapy in patients with advanced non-small cell lung cancer
Latest Information Update: 27 Oct 2022
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 27 Oct 2022 New trial record
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress